Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized study of TAR-210 versus intravesical chemotherapy in FGFR-altered intermediate-risk non-muscle-invasive bladder cancer
MOH_2024-04-15_013372Phase 3Recruiting
- Sponsor
- J-C Health Care
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of Erda-iDRS in bladder cancer and non-muscle-invasive bladder cancer (NMIBC) (4 arms), sponsored by J-C Health Care. Primary endpoint: Recurrence-free or progression-free survival. Started Apr 2024; status: recruiting.
02
Drugs
Erda-iDRS
03
Conditions
bladder cancernon-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on MOH_2024-04-15_013372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-04-15_013372.